News & Updates

Prior to the COVID-19 pandemic, life expectancy at age 70 years has continued to rise across the globe due to reductions in chronic diseases, according to a recent study. However, disability burden persists and indicates the need to improve public health and intervention initiatives to enhance well-being among older adults.

In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.

Patients with childhood-onset chronic rheumatic disease (CRD) do not perform as well as their peers on grade 12 standardized testing, independent of sociodemographic and mental health comorbidities, reports a population-based retrospective cohort study.

Trajectories of body roundness index (BRI) appear to predict the risk of cardiovascular disease (CVD), particularly among younger adults, suggests a study.

The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.